Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shuren At FDLI: Least-Burdensome, Real-World Evidence Efforts Picking Up

Executive Summary

US FDA's device-center head discussed his continued push to make regulations more flexible, plans for least-burdensome training and what's next for NEST, among other topics, at the Food & Drug Law Institute annual gathering in Washington DC.

Advertisement

Related Content

A New NEST: MDIC Leaders Discuss Relocation, National Evaluation System And More
US FDA Warning Letter Scrutinizes Abbott Over Cybersecurity, Battery Lapses
FDA 510(k)-Exempts 72 Devices, Mostly Diagnostics
23andMe Opens Up FDA Pathway For DTC Genetic Predisposition Tests
Single Marketing Application Review For Multiple Jurisdictions On Horizon
More Manufacturers Sign Up For Single Audits As MDSAP Becomes Operational
US FDA Could Be Mostly Spared From Trump's Regulation-Slashing Order
Pilot Of New US Evaluation System Will Include At Least Two Devices
MDIC Project Looks To New P-Value Possibilities
Shuren To Industry: 'Hire A Hacker'

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT104839

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel